Oxford BioTherapeutics Ltd

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines for oncology. OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. Through its alliances with the world leaders in antibody development (Medarex, Biosite and Amgen), OBT is in an unrivalled position to convert its novel targets into a successful therapeutic pipeline. OBT’s pipeline will deliver innovative and cost-effective medicines to fulfil major unmet patient needs in the field of cancer. OBT, a privately held company, was formed in 2004 and is based near Oxford, UK.